Athena Athena

X

Find Drugs in Development News & Deals for Alogliptin Benzoate

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

Details:

The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.


Lead Product(s): Alogliptin Benzoate,Pioglitazone

Therapeutic Area: Endocrinology Product Name: Liovel

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Teijin Pharma

Deal Size: $1,250.0 million Upfront Cash: Undisclosed

Deal Type: Divestment April 01, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.


Lead Product(s): Alogliptin Benzoate

Therapeutic Area: Endocrinology Product Name: Nesina

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Teijin Pharma

Deal Size: $1,250.0 million Upfront Cash: Undisclosed

Deal Type: Divestment February 26, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.


Lead Product(s): Alogliptin Benzoate

Therapeutic Area: Endocrinology Product Name: Nesina

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Celltrion

Deal Size: $278.0 million Upfront Cash: $266.0 million

Deal Type: Divestment June 11, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY